Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Core Insights - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders [1][3] - The company will present at the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 8:10 AM ET [1] - The webcast of the presentation will be available on the company's website and accessible for 60 days [2] Company Overview - Bright Minds Biosciences is a biotechnology company dedicated to innovative treatments for neurological and psychiatric disorders [3] - The company's pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical needs [3][4] - Bright Minds has developed a unique platform of highly selective serotonergic agonists, providing a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [4]